West Pharmaceutical Services, Inc. (WST): Price and Financial Metrics


West Pharmaceutical Services, Inc. (WST)

Today's Latest Price: $281.64 USD

4.43 (-1.55%)

Updated Oct 28 2:31pm

Add WST to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

WST Stock Summary

  • West Pharmaceutical Services Inc's market capitalization of $20,707,744,631 is ahead of 90.69% of US-listed equities.
  • West Pharmaceutical Services Inc's stock had its IPO on January 5, 1988, making it an older stock than 89.3% of US equities in our set.
  • Price to trailing twelve month operating cash flow for WST is currently 48.14, higher than 92.37% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to West Pharmaceutical Services Inc, a group of peers worth examining would be PAYC, TECH, MKTX, LOGI, and HAE.
  • WST's SEC filings can be seen here. And to visit West Pharmaceutical Services Inc's official web site, go to www.westpharma.com.

WST Stock Price Chart Interactive Chart >

Price chart for WST

WST Price/Volume Stats

Current price $281.64 52-week high $303.14
Prev. close $286.07 52-week low $124.53
Day low $276.40 Volume 313,320
Day high $284.26 Avg. volume 609,046
50-day MA $279.50 Dividend yield 0.22%
200-day MA $216.17 Market Cap 20.82B

West Pharmaceutical Services, Inc. (WST) Company Bio


West Pharmaceutical Services develops, manufactures, and sells components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The company operates through two segments, Pharmaceutical Packaging Systems and Pharmaceutical Delivery Systems. The company was founded in 1923 and is based in Exton, Pennsylvania.

WST Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$281.64$91.57 -67%

Below please find a table outlining a discounted cash flow forecast for WST, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that West Pharmaceutical Services Inc ranked in the 22th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 67.17%. As for the metrics that stood out in our discounted cash flow analysis of West Pharmaceutical Services Inc, consider:

  • Interest coverage, a measure of earnings relative to interest payments, is 47.38 -- which is good for besting 92.38% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 7.13% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • WST's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.75% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-68%
1%-68%
2%-67%
3%-67%
4%-67%
5%-66%

GMED, OFIX, TMO, ABT, and BAX can be thought of as valuation peers to WST, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


WST Latest News Stream


Event/Time News Detail
Loading, please wait...

WST Latest Social Stream


Loading social stream, please wait...

View Full WST Social Stream

Latest WST News From Around the Web

Below are the latest news stories about West Pharmaceutical Services Inc that investors may wish to consider to help them evaluate WST as an investment opportunity.

The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ...

Benzinga | September 3, 2020

The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics...

Benzinga | September 2, 2020

Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.

Yahoo | July 31, 2020

West Pharmaceutical's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in West Pharmaceutical Services.

Yahoo | July 30, 2020

West Pharmaceutical Services (WST) Q2 2020 Earnings Call Transcript

WST earnings call for the period ending June 30, 2020.

Yahoo | July 24, 2020

Read More 'WST' Stories Here

WST Price Returns

1-mo 3.40%
3-mo 4.71%
6-mo 47.05%
1-year 96.86%
3-year 182.16%
5-year 381.93%
YTD 87.83%
2019 54.13%
2018 -0.08%
2017 17.02%
2016 41.87%
2015 14.03%

WST Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full WST Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.8333 seconds.